IP Library Granted Patent US 11,833,364
Granted Patent B2
US 11,833,364 · App. 17/162,482 · Granted Dec 5, 2023

Tissue treatment apparatus and systems with pain mitigation and methods for mitigating pain during tissue treatments

Inventors: Dragan D. Nebrigic (Carlsbad, CA); Thomas Markiewicz (Los Gatos, CA)
Assignee: Solta Medical, Inc.
A61N5/00A61B18/14A61N1/403A61B2018/00011A61B2018/00452A61B2018/1467
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,833,364
App. No.
17/162,482
Granted
Dec 5, 2023
Kind
B2
Abstract

Methods, apparatus, and systems for delivering electromagnetic energy to a patient's tissue with a reduction in the pain experienced by the patient. Electromagnetic energy is delivered from a treatment electrode through the skin surface to the tissue at a plurality of power levels over a treatment time. During the energy delivery, a portion of the treatment electrode is in a contacting relationship with the skin surface. A tip frame may be disposed between the treatment electrode and the skin surface when the electromagnetic energy is delivered.

Claims (27)

1. A system configured to treat tissue with electromagnetic energy, the system comprising:

a generator configured to generate the electromagnetic energy;

a first treatment electrode coupled with the generator; and

a system controller coupled with the generator, the system controller configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode with a power profile having a plurality of differing power levels over a treatment time divided into a plurality of time intervals each associated with a respective one of the differing power levels, the differing power levels ranging from a first power that is at least 20 percent above a nominal power of 200 joules per second to a second power that is at least 20 percent below the nominal power of 200 joules per second, and the system controller configured to cause the plurality of differing power levels to be provided with open loop control over the power profile.

2. The system of claim 1 further comprising:

a handpiece.

3. The system of claim 2 comprising:

a treatment tip coupled in a removable manner with the handpiece,

wherein the treatment tip includes the first treatment electrode.

4. The system of claim 1 further comprising

a second treatment electrode coupled with the generator.

5. The system of claim 4 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode and to the second treatment electrode at the differing power levels over the treatment time.

6. The system of claim 4 further comprising:

a multiplexer configured to selectively couple the first treatment electrode and the second treatment electrode with the generator.

7. The system of claim 4 wherein the system controller is configured to cause the electromagnetic energy to be simultaneously provided from the generator to the first treatment electrode and to the second treatment electrode at the differing power levels over the treatment time.

8. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode such that the differing power levels decrease in power as the treatment time increases.

9. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode such that the time intervals are isochronal over the treatment time.

10. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode in sequential steps between the differing power levels over the treatment time.

11. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode on a timed basis.

12. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode such that a length of the time intervals increases with increasing time over the treatment time.

13. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode such that a length of the time intervals decreases with increasing time over the treatment time.

14. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode at a different power for at least two of the differing power levels.

15. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode with a power at each of the differing power levels maintained constant at a percentage of a target power.

16. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode with a maximum power supplied during an initial time interval and a minimum power supplied during a final time interval.

17. The system of claim 1 wherein the system controller is configured to cause the electromagnetic energy to be provided from the generator to the first treatment electrode with a maximum power and a minimum power supplied at different time intervals between an initial time interval and a final time interval.

18. The system of claim 1 wherein the system controller further includes a user interface configured to deliver instructions to the system controller containing a plurality of parameters relating to the power profile, and a memory configured to store the parameters for the power profile.

19. The system of claim 1 wherein the system controller is configured to cause the plurality of differing power levels of the power profile to be provided without feedback.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded May 20, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH + LOMB IRELAND LIMITED; BAUSCH HEALTH US, LLC; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 056304/0556 →
SECURITY INTEREST Recorded May 20, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH + LOMB IRELAND LIMITED; BAUSCH HEALTH US, LLC; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056304/0581 →
Continuity (6)
Continuation 16275632 · Feb 14, 2019
Continuation 14339667 · Jul 24, 2014
Continuation 12649909 · Dec 30, 2009
Provisional Application 61226138 · Jul 16, 2009
Provisional Application 61143537 · Jan 9, 2009
Related Publication 20210228899A1 · Jul 29, 2021